Benzinga

Benzinga

Benzinga

lunedì, agosto 31

Chemed Corp

CHENYSE
Trade with Public
Trade with Public
$518.71
-4.67-0.89%
In chiusura: Aug 31, 5:00 PM EST
$518.85
0.140.03%
Post-mercato: 5:21 PM EST
PanoramicaNotiziePrevisioni utiliEventiObiettivi di prezzoDati finanziariSentimentAzionariatoDividendiConfrontaOpzioniRapporto azionario

Chemed Analyst Price Targets

Wall Street analyst price targets and consensus rating for Chemed (CHE).

Price Target Range — 11 Quarters

Analyst Consensus — 4 Analysts

1Buy
3Hold
Consensus RatingOutperform# Analysts4Avg. Consensus PT$531Upside to Avg. PT+2.3%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Jul 31, 2026OppenheimerMichael WiederhornPT RaiseOutperform$500→$590
Jul 30, 2026RBC CapitalBen HendrixPT RaiseSector Perform$436→$548
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Oppenheimer Maintains Outperform on Chemed, Raises Price Target to $590

Oppenheimer analyst Michael Wiederhorn maintains Chemed (NYSE:CHE) with a Outperform and raises the price target from $500 to $590.
Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Chemed, Raises Price Target to $548

RBC Capital analyst Ben Hendrix maintains Chemed (NYSE:CHE) with a Sector Perform and raises the price target from $436 to $548.
Benzinga Newsdesk

PRO
B of A Securities Maintains Neutral on Chemed, Raises Price Target to $510

B of A Securities analyst Joanna Gajuk maintains Chemed (NYSE:CHE) with a Neutral and raises the price target from $450 to $510.
Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Chemed, Raises Price Target to $436

RBC Capital analyst Ben Hendrix maintains Chemed (NYSE:CHE) with a Sector Perform and raises the price target from $422 to $436.
Benzinga Newsdesk

PRO
RBC Capital Downgrades Chemed to Sector Perform, Lowers Price Target to $422

RBC Capital analyst Ben Hendrix downgrades Chemed (NYSE:CHE) from Outperform to Sector Perform and lowers the price target from $572 to $422.
Benzinga Newsdesk

PRO
Oppenheimer Maintains Outperform on Chemed, Lowers Price Target to $500

Oppenheimer analyst Michael Wiederhorn maintains Chemed (NYSE:CHE) with a Outperform and lowers the price target from $580 to $500.
Benzinga Newsdesk

Dati e API: API Benzinga · API notizie azionarie · API valutazioni analisti · API logo aziende

Dati di mercato forniti da API Benzinga

Benzinga

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO

© 2026 Benzinga | All Rights Reserved